<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Gastroenterol</journal-id><journal-title-group><journal-title>BMC Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">1471-230X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19922626</article-id><article-id pub-id-type="pmc">2784471</article-id><article-id pub-id-type="publisher-id">1471-230X-9-84</article-id><article-id pub-id-type="doi">10.1186/1471-230X-9-84</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effects of esomeprazole treatment for gastroesophageal reflux disease on quality of life in 12- to 17-year-old adolescents: an international health outcomes study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Gunasekaran</surname><given-names>Thirumazhisai</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ts.gunasekaran-md@advocatehealth.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Tolia</surname><given-names>Vasundhara</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I7">7</xref><email>vasu.tolia@gmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Colletti</surname><given-names>Richard B</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Richard.Colletti@uvm.edu</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Gold</surname><given-names>Benjamin D</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>Ben.Gold@oz.ped.emory.edu</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Traxler</surname><given-names>Barry</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>Barry.Traxler@astrazeneca.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Illueca</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>Marta.Illueca@astrazeneca.com</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Crawley</surname><given-names>Joseph A</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>Joe.Crawley@astrazeneca.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Lutheran General Children's Hospital, 1675 Dempster Street, Park Ridge, IL 60068, USA </aff><aff id="I2"><label>2</label>Loyola Medical Center, 2160 South 1st Street, Maywood, IL 60153, USA</aff><aff id="I3"><label>3</label>Wayne State University, 4743 Cass Avenue, Detroit, MI 48201, USA</aff><aff id="I4"><label>4</label>University of Vermont, 201 South Prospect Street, Burlington, VT 05401, USA</aff><aff id="I5"><label>5</label>Emory University School of Medicine, 1648 Pierce Drive, Atlanta, GA 30322, USA</aff><aff id="I6"><label>6</label>AstraZeneca LP, 1800 Concord Pike, Wilmington, DE 19803, USA</aff><aff id="I7"><label>7</label>Providence Hospital, Southfield, MI, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>18</day><month>11</month><year>2009</year></pub-date><volume>9</volume><fpage>84</fpage><lpage>84</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2009</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2009</year></date></history><permissions><copyright-statement>Copyright Â©2009 Gunasekaran et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Gunasekaran et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-230X/9/84"></self-uri><abstract><sec><title><offsets xml_i="4517" xml_f="4527" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4538" xml_f="4819" txt_i="22" txt_f="303">Although gastroesophageal reflux disease (GERD) is common in adolescents, the burden of GERD on health-related quality of life (HRQOL) in adolescents has not been previously evaluated. Therefore, the objective of the study was to examine the effect of GERD on HRQOL in adolescents.</offsets></p></sec><sec><title><offsets xml_i="4841" xml_f="4848" txt_i="305" txt_f="312">Methods</offsets></title><p><offsets xml_i="4859" xml_f="5343" txt_i="313" txt_f="797">This international, 31-site, 8-week safety study randomized adolescents, aged 12 to 17 years inclusive, with GERD to receive esomeprazole 20 or 40 mg once daily. The Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD), previously validated in adults, consists of 25 questions grouped into 5 domains: emotional distress, sleep disturbance, food/drink problems, physical/social functioning, and vitality. The QOLRAD was administered at the baseline and week-8 (final) visits.</offsets></p></sec><sec><title><offsets xml_i="5365" xml_f="5372" txt_i="799" txt_f="806">Results</offsets></title><p><offsets xml_i="5383" xml_f="5789" txt_i="807" txt_f="1213">Of the 149 patients randomized, 134 completed the QOLRAD at baseline and final visits and were eligible for analysis of their HRQOL data. Baseline QOLRAD scores indicated GERD had a negative effect on the HRQOL of these adolescents, especially in the domains of vitality and emotional distress, and problems with food/drink. At the final visit, mean scores for all 5 QOLRAD domains improved significantly (</offsets><italic><offsets xml_i="5797" xml_f="5799" txt_i="1213" txt_f="1215">P </offsets></italic><offsets xml_i="5808" xml_f="5963" txt_i="1215" txt_f="1367">&lt; .0001); change of scores (ie, delta) for all domains met or exceeded the adult QOLRAD minimal clinically significant difference standard of 0.5 units.</offsets></p></sec><sec><title><offsets xml_i="5985" xml_f="5995" txt_i="1369" txt_f="1379">Conclusion</offsets></title><p><offsets xml_i="6006" xml_f="6200" txt_i="1380" txt_f="1574">GERD had a negative effect on QOL in adolescents. After esomeprazole treatment, statistically and clinically significant improvements occurred in all domains of the QOLRAD for these adolescents.</offsets></p></sec><sec><title><offsets xml_i="6222" xml_f="6240" txt_i="1576" txt_f="1594">Trial Registration</offsets></title><p><offsets xml_i="6251" xml_f="6305" txt_i="1595" txt_f="1649">D9614C00098; ClinicalTrials.gov Identifier NCT00241501</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="6367" xml_f="6377" txt_i="1658" txt_f="1668">Background</offsets></title><p><offsets xml_i="6388" xml_f="6492" txt_i="1669" txt_f="1773">Gastroesophageal reflux disease (GERD) is recognized increasingly as a common condition in adolescents [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6523" xml_f="6524" txt_i="1773" txt_f="1774">1</offsets></xref><offsets xml_i="6531" xml_f="6667" txt_i="1774" txt_f="1910">]. Recent surveys of high school students show that at least 21% had significant GERD symptoms occurring a minimum of 1 time per month [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6698" xml_f="6699" txt_i="1910" txt_f="1911">2</offsets></xref><offsets xml_i="6706" xml_f="6707" txt_i="1911" txt_f="1912">-</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6738" xml_f="6739" txt_i="1912" txt_f="1913">4</offsets></xref><offsets xml_i="6746" xml_f="6979" txt_i="1913" txt_f="2146">]. A survey conducted in pediatric practices revealed that 5.2%, 5.0%, and 8.2% of children and adolescents aged 10 to 17 years reported experiencing heartburn, epigastric pain, and regurgitation, respectively, in the previous week [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7010" xml_f="7011" txt_i="2146" txt_f="2147">5</offsets></xref><offsets xml_i="7018" xml_f="7154" txt_i="2147" txt_f="2283">]. Moreover, in the same time period, 27.9% of children aged 10 to 17 years experienced abdominal pain, which may be a symptom of GERD [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7185" xml_f="7186" txt_i="2283" txt_f="2284">5</offsets></xref><offsets xml_i="7193" xml_f="7195" txt_i="2284" txt_f="2286">].</offsets></p><p><offsets xml_i="7202" xml_f="7415" txt_i="2287" txt_f="2500">Findings of numerous studies have shown the negative effect of GERD on health-related quality of life (HRQOL) in adults; however, few studies have assessed the effect of GERD on HRQOL in children and adolescents [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7446" xml_f="7447" txt_i="2500" txt_f="2501">6</offsets></xref><offsets xml_i="7454" xml_f="7455" txt_i="2501" txt_f="2502">-</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="7487" xml_f="7489" txt_i="2502" txt_f="2504">15</offsets></xref><offsets xml_i="7496" xml_f="7540" txt_i="2504" txt_f="2548">]. Although previously validated in adults [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="7572" xml_f="7574" txt_i="2548" txt_f="2550">16</offsets></xref><offsets xml_i="7581" xml_f="7785" txt_i="2550" txt_f="2754">], no data are available on the validity and performance of the Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD) in adolescent GERD patients or on the burden of GERD on HRQOL in adolescents.</offsets></p><p><offsets xml_i="7792" xml_f="7926" txt_i="2755" txt_f="2889">Proton pump inhibitors (PPIs) have been recommended as the most effective acid suppression therapy for adults and children with GERD [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="7958" xml_f="7960" txt_i="2889" txt_f="2891">17</offsets></xref><offsets xml_i="7967" xml_f="7968" txt_i="2891" txt_f="2892">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="8000" xml_f="8002" txt_i="2892" txt_f="2894">18</offsets></xref><offsets xml_i="8009" xml_f="8107" txt_i="2894" txt_f="2992">]. PPIs have been shown to relieve or resolve GERD symptoms in most adult and pediatric patients [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="8139" xml_f="8141" txt_i="2992" txt_f="2994">19</offsets></xref><offsets xml_i="8148" xml_f="8149" txt_i="2994" txt_f="2995">-</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="8181" xml_f="8183" txt_i="2995" txt_f="2997">23</offsets></xref><offsets xml_i="8190" xml_f="8309" txt_i="2997" txt_f="3116">]. In Gold et al, we reported the safety and efficacy of esomeprazole in treating the symptoms of GERD in adolescents [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="8341" xml_f="8343" txt_i="3116" txt_f="3118">23</offsets></xref><offsets xml_i="8350" xml_f="8471" txt_i="3118" txt_f="3239">]. In the current article, we explore the effects of esomeprazole on QOL in the adolescent patients from the Gold et al [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="8503" xml_f="8505" txt_i="3239" txt_f="3241">23</offsets></xref><offsets xml_i="8512" xml_f="8520" txt_i="3241" txt_f="3249">] study.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="8561" xml_f="8568" txt_i="3251" txt_f="3258">Methods</offsets></title><sec><title><offsets xml_i="8588" xml_f="8600" txt_i="3259" txt_f="3271">Study design</offsets></title><p><offsets xml_i="8611" xml_f="9199" txt_i="3272" txt_f="3860">This international, phase 3, randomized study double blinded for dose safety was conducted at 31 sites in Canada, France, Italy, and the United States (D9614C00098; ClinicalTrials.gov Identifier NCT00241501). The study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with ICH/Good Clinical Practice. The study protocol was approved by the institutional review boards, and all patients and their parents or guardians provided written informed consent and assent before any study procedure was conducted.</offsets></p><p><offsets xml_i="9206" xml_f="9266" txt_i="3861" txt_f="3921">Patients were randomized 1:1 to receive esomeprazole (Nexium</offsets><sup><offsets xml_i="9271" xml_f="9272" txt_i="3921" txt_f="3922">Â®</offsets></sup><offsets xml_i="9278" xml_f="9639" txt_i="3922" txt_f="4283">; AstraZeneca LP, Wilmington, DE) 20 or 40 mg (no placebo control) orally once daily for 8 weeks. Esomeprazole was administered approximately 60 minutes before breakfast. For patients unable to swallow capsules, capsule contents could be mixed with 1 tablespoon of applesauce. Age-appropriate chewable antacid tablets were provided for use as rescue medication.</offsets></p></sec><sec><title><offsets xml_i="9661" xml_f="9669" txt_i="4285" txt_f="4293">Patients</offsets></title><p><offsets xml_i="9680" xml_f="10114" txt_i="4294" txt_f="4728">Adolescents aged 12 to 17 years with a clinical diagnosis of GERD based on medical history, physical examination, any laboratory test results, and/or information from any diagnostic testing (eg, pH monitoring, endoscopy, biopsy) were eligible to participate in the study. The study entry criteria were consistent with GERD diagnostic guidelines of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="10146" xml_f="10148" txt_i="4728" txt_f="4730">17</offsets></xref><offsets xml_i="10155" xml_f="10190" txt_i="4730" txt_f="4765">]. Patients who were infected with </offsets><italic><offsets xml_i="10198" xml_f="10218" txt_i="4765" txt_f="4785">Helicobacter pylori </offsets></italic><offsets xml_i="10227" xml_f="11065" txt_i="4785" txt_f="5623">(as documented by the investigator using standard medical practice) but had no evidence of active ulceration or recent gastrointestinal bleeding were permitted at the discretion of the investigator. Postpubertal girls must have had a negative result on their urine pregnancy tests at the screening and week-4 and -8 visits. Patients who had any gastrointestinal pathology that required surgery, interfered with study participation, or potentially confounded study data were excluded. Patients who had an acute or chronic illness or condition (eg, pervasive developmental disorders, suspected abuse/neglect, recent trauma) that, in the opinion of the investigator, placed the patient at risk for not completing the study or for potentially confounding the study data were excluded. Patients could not have taken any PPI within 14 days or H</offsets><sub><offsets xml_i="11070" xml_f="11071" txt_i="5623" txt_f="5624">2</offsets></sub><offsets xml_i="11077" xml_f="11339" txt_i="5624" txt_f="5886">-receptor antagonist or prokinetic agent within 3 days of randomization. Patients also could not use any study-restricted medications (eg, antiemetics, bismuth-containing products, macrolide antibiotics, systemic steroids) on a continuous basis during the study.</offsets></p></sec><sec><title><offsets xml_i="11361" xml_f="11372" txt_i="5888" txt_f="5899">Assessments</offsets></title><p><offsets xml_i="11383" xml_f="11427" txt_i="5900" txt_f="5944">The QOLRAD, previously validated in adults [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="11459" xml_f="11461" txt_i="5944" txt_f="5946">16</offsets></xref><offsets xml_i="11468" xml_f="11688" txt_i="5946" txt_f="6166">], generally can be completed in approximately 12 to 15 minutes and consists of 25 questions grouped into 5 domains: emotional distress, sleep disturbance, food/drink problems, vitality, and physical/social functioning [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="11720" xml_f="11722" txt_i="6166" txt_f="6168">16</offsets></xref><offsets xml_i="11729" xml_f="11879" txt_i="6168" txt_f="6318">]. The QOLRAD also has been translated and cross-culturally validated into languages including French, German, Spanish, Italian, and French Canadian [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="11911" xml_f="11913" txt_i="6318" txt_f="6320">24</offsets></xref><offsets xml_i="11920" xml_f="12440" txt_i="6320" txt_f="6840">]. The QOLRAD was administered at the randomization (baseline) and week-8 (final) visits. Responses were based on a 1-week recall period and scored using a 7-point Likert response scale (1 = all of the time/a great deal; 7 = none of the time/none at all); higher scores indicated better QOL. Administration of the QOLRAD was standardized, and procedures were used throughout the study to enhance patient compliance in correctly completing the QOLRAD, such as quiet, privacy, and administration before other examinations.</offsets></p></sec><sec><title><offsets xml_i="12462" xml_f="12482" txt_i="6842" txt_f="6862">Statistical analyses</offsets></title><p><offsets xml_i="12493" xml_f="12730" txt_i="6863" txt_f="7100">Data from patients in both treatment groups were pooled for analysis, and between-group comparisons were not made. Mean total scores and individual domain scores were calculated at baseline and final visits and compared using the paired </offsets><italic><offsets xml_i="12738" xml_f="12740" txt_i="7100" txt_f="7102">t </offsets></italic><offsets xml_i="12749" xml_f="12873" txt_i="7102" txt_f="7226">test. Mean change in score between baseline and the final visit was considered clinically significant if 0.5 or more units [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="12904" xml_f="12905" txt_i="7226" txt_f="7227">9</offsets></xref><offsets xml_i="12912" xml_f="13104" txt_i="7227" txt_f="7419">]. This minimally clinically significant change was established based on findings from a previously conducted study assessing the reliability and responsiveness to change over time of QOLRAD [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="13135" xml_f="13136" txt_i="7419" txt_f="7420">9</offsets></xref><offsets xml_i="13143" xml_f="13290" txt_i="7420" txt_f="7567">]. Missing item responses were replaced by the mean value of completed items in that domain if 50% or more items in that domain had been completed.</offsets></p><p><offsets xml_i="13297" xml_f="13460" txt_i="7568" txt_f="7731">A post hoc assessment was conducted to compare baseline QOLRAD scores from adolescents in this study with those of adults in the previous QOLRAD validation study [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="13492" xml_f="13494" txt_i="7731" txt_f="7733">16</offsets></xref><offsets xml_i="13501" xml_f="13651" txt_i="7733" txt_f="7883">]. Though the methods and primary results of the QOLRAD validation study were published previously, baseline scores had not been reported previously [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="13683" xml_f="13685" txt_i="7883" txt_f="7885">16</offsets></xref><offsets xml_i="13692" xml_f="14186" txt_i="7885" txt_f="8379">]. Briefly, the adult study was an international, multicenter psychometric evaluation in which 759 adult patients with chronic or recurrent upper gastrointestinal symptoms completed the QOLRAD. In the analysis presented here, mean baseline QOLRAD scores from each of the 5 domains were calculated according to baseline heartburn severity (mild, moderate, severe). Differences in QOLRAD scores 0.5 or more units between adult and adolescent patients were considered to be clinically significant.</offsets></p></sec></sec><sec><title><offsets xml_i="14214" xml_f="14221" txt_i="8382" txt_f="8389">Results</offsets></title><p><offsets xml_i="14232" xml_f="14354" txt_i="8390" txt_f="8512">Of the 149 patients randomized, more were girls (59.7%) and white (83.2%) and the mean body mass index was 23.5 Â± 4.9 kg/m</offsets><sup><offsets xml_i="14359" xml_f="14360" txt_i="8512" txt_f="8513">2</offsets></sup><offsets xml_i="14366" xml_f="14449" txt_i="8513" txt_f="8596">. Of these 149 patients, 134 completed the QOLRAD at the baseline and final visits.</offsets></p><p><offsets xml_i="14456" xml_f="14498" txt_i="8597" txt_f="8639">Baseline QOLRAD mean total scores (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14528" xml_f="14529" txt_i="8639" txt_f="8640">1</offsets></xref><offsets xml_i="14536" xml_f="14569" txt_i="8640" txt_f="8673">) and mean domain scores (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="14599" xml_f="14600" txt_i="8673" txt_f="8674">2</offsets></xref><offsets xml_i="14607" xml_f="14835" txt_i="8674" txt_f="8902">) indicated that GERD had a negative effect on the HRQOL of these patients compared with normal adults. The QOLRAD domains most negatively affected by GERD were vitality, emotional distress, and problems with food/drink (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="14865" xml_f="14866" txt_i="8902" txt_f="8903">2</offsets></xref><offsets xml_i="14873" xml_f="14875" txt_i="8903" txt_f="8905">).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="14916" xml_f="14924" txt_i="8906" txt_f="8914">Figure 1</offsets></label><caption><p><bold><offsets xml_i="14950" xml_f="15030" txt_i="8914" txt_f="8994">Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD) mean total scores</offsets></bold><offsets xml_i="15037" xml_f="15203" txt_i="8994" txt_f="9160">. QOLRAD mean total scores Â± standard deviation at baseline and final visit (both based on a 1-week recall) (n = 134). Higher scores indicate better quality of life. </offsets><sup><offsets xml_i="15208" xml_f="15209" txt_i="9160" txt_f="9161">a</offsets></sup><italic><offsets xml_i="15223" xml_f="15225" txt_i="9161" txt_f="9163">P </offsets></italic><offsets xml_i="15234" xml_f="15256" txt_i="9163" txt_f="9182">&lt; .001 vs baseline.</offsets></p></caption><graphic xlink:href="1471-230X-9-84-1"></graphic></fig><fig id="F2" position="float"><label><offsets xml_i="15362" xml_f="15370" txt_i="9183" txt_f="9191">Figure 2</offsets></label><caption><p><bold><offsets xml_i="15396" xml_f="15477" txt_i="9191" txt_f="9272">Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD) mean domain scores</offsets></bold><offsets xml_i="15484" xml_f="15651" txt_i="9272" txt_f="9439">. QOLRAD mean domain scores Â± standard deviation at baseline and final visit (both based on a 1-week recall) (n = 134). Higher scores indicate better quality of life. </offsets><sup><offsets xml_i="15656" xml_f="15657" txt_i="9439" txt_f="9440">a</offsets></sup><italic><offsets xml_i="15671" xml_f="15673" txt_i="9440" txt_f="9442">P </offsets></italic><offsets xml_i="15682" xml_f="15704" txt_i="9442" txt_f="9461">&lt; .001 vs baseline.</offsets></p></caption><graphic xlink:href="1471-230X-9-84-2"></graphic></fig><p><offsets xml_i="15776" xml_f="15912" txt_i="9462" txt_f="9598">QOLRAD mean total scores and mean domain scores were improved significantly from baseline values after 8 weeks of esomeprazole therapy (</offsets><italic><offsets xml_i="15920" xml_f="15922" txt_i="9598" txt_f="9600">P </offsets></italic><offsets xml_i="15931" xml_f="15951" txt_i="9600" txt_f="9617">&lt; .001) (Figures </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="15981" xml_f="15982" txt_i="9617" txt_f="9618">1</offsets></xref><offsets xml_i="15989" xml_f="15994" txt_i="9618" txt_f="9623"> and </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16024" xml_f="16025" txt_i="9623" txt_f="9624">2</offsets></xref><offsets xml_i="16032" xml_f="16223" txt_i="9624" txt_f="9815">). Mean changes from baseline values in the QOLRAD total and domain scores met or exceeded the established adult QOLRAD minimum clinically significant difference standard of 0.5 units (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="16255" xml_f="16256" txt_i="9815" txt_f="9816">1</offsets></xref><offsets xml_i="16263" xml_f="16266" txt_i="9816" txt_f="9819">) [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="16297" xml_f="16298" txt_i="9819" txt_f="9820">9</offsets></xref><offsets xml_i="16305" xml_f="16307" txt_i="9820" txt_f="9822">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="16355" xml_f="16362" txt_i="9823" txt_f="9830">Table 1</offsets></label><caption><p><offsets xml_i="16382" xml_f="16468" txt_i="9830" txt_f="9916">Mean changes in QOLRAD total and domain scores from baseline to final visit (n = 134).</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center"><offsets xml_i="16549" xml_f="16562" txt_i="9917" txt_f="9930">QOLRAD Domain</offsets></th><th align="center"><offsets xml_i="16586" xml_f="16607" txt_i="9930" txt_f="9951">Change in Mean Scores</offsets><sup><offsets xml_i="16612" xml_f="16613" txt_i="9951" txt_f="9952">a</offsets></sup></th><th align="center"><offsets xml_i="16643" xml_f="16695" txt_i="9952" txt_f="10004">Number of patients who significantly improved, n (%)</offsets><sup><offsets xml_i="16700" xml_f="16701" txt_i="10004" txt_f="10005">b</offsets></sup></th><th align="center"><offsets xml_i="16731" xml_f="16783" txt_i="10005" txt_f="10057">Number of patients who significantly worsened, n (%)</offsets><sup><offsets xml_i="16788" xml_f="16789" txt_i="10057" txt_f="10058">b</offsets></sup></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="16841" xml_f="16859" txt_i="10058" txt_f="10076">Emotional distress</offsets></td><td align="center"><offsets xml_i="16883" xml_f="16887" txt_i="10077" txt_f="10081">0.83</offsets></td><td align="center"><offsets xml_i="16911" xml_f="16920" txt_i="10082" txt_f="10091">67 (50.0)</offsets></td><td align="center"><offsets xml_i="16944" xml_f="16952" txt_i="10092" txt_f="10100">10 (7.5)</offsets></td></tr><tr><td align="left"><offsets xml_i="16983" xml_f="17000" txt_i="10101" txt_f="10118">Sleep disturbance</offsets></td><td align="center"><offsets xml_i="17024" xml_f="17028" txt_i="10119" txt_f="10123">0.65</offsets></td><td align="center"><offsets xml_i="17052" xml_f="17061" txt_i="10124" txt_f="10133">61 (45.5)</offsets></td><td align="center"><offsets xml_i="17085" xml_f="17093" txt_i="10134" txt_f="10142">13 (9.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="17124" xml_f="17143" txt_i="10143" txt_f="10162">Food/drink problems</offsets></td><td align="center"><offsets xml_i="17167" xml_f="17171" txt_i="10163" txt_f="10167">1.07</offsets></td><td align="center"><offsets xml_i="17195" xml_f="17204" txt_i="10168" txt_f="10177">85 (63.4)</offsets></td><td align="center"><offsets xml_i="17228" xml_f="17235" txt_i="10178" txt_f="10185">9 (6.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="17266" xml_f="17274" txt_i="10186" txt_f="10194">Vitality</offsets></td><td align="center"><offsets xml_i="17298" xml_f="17302" txt_i="10195" txt_f="10199">0.79</offsets></td><td align="center"><offsets xml_i="17326" xml_f="17335" txt_i="10200" txt_f="10209">73 (54.5)</offsets></td><td align="center"><offsets xml_i="17359" xml_f="17368" txt_i="10210" txt_f="10219">17 (12.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="17399" xml_f="17426" txt_i="10220" txt_f="10247">Physical/social functioning</offsets></td><td align="center"><offsets xml_i="17450" xml_f="17454" txt_i="10248" txt_f="10252">0.50</offsets></td><td align="center"><offsets xml_i="17478" xml_f="17487" txt_i="10253" txt_f="10262">56 (41.8)</offsets></td><td align="center"><offsets xml_i="17511" xml_f="17519" txt_i="10263" txt_f="10271">13 (9.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="17550" xml_f="17561" txt_i="10272" txt_f="10283">Total score</offsets></td><td align="center"><offsets xml_i="17585" xml_f="17589" txt_i="10284" txt_f="10288">0.77</offsets></td><td align="center"><offsets xml_i="17613" xml_f="17614" txt_i="10289" txt_f="10290">-</offsets></td><td align="center"><offsets xml_i="17638" xml_f="17639" txt_i="10291" txt_f="10292">-</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="17685" xml_f="17761" txt_i="10293" txt_f="10369">Abbreviation: QOLRAD, Quality of Life in Reflux and Dyspepsia questionnaire.</offsets></p><p><sup><offsets xml_i="17773" xml_f="17774" txt_i="10370" txt_f="10371">a</offsets></sup><italic><offsets xml_i="17788" xml_f="17790" txt_i="10371" txt_f="10373">P </offsets></italic><offsets xml_i="17799" xml_f="17811" txt_i="10373" txt_f="10382">&lt; .0001; </offsets><sup><offsets xml_i="17816" xml_f="17817" txt_i="10382" txt_f="10383">b</offsets></sup><offsets xml_i="17823" xml_f="17923" txt_i="10383" txt_f="10483">Significant improvement and significant worsening defined as a change in score of 0.5 from baseline.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="17961" xml_f="18054" txt_i="10484" txt_f="10577">At baseline, QOLRAD scores were similar in adolescents and adults with mild heartburn (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="18086" xml_f="18087" txt_i="10577" txt_f="10578">2</offsets></xref><offsets xml_i="18094" xml_f="18509" txt_i="10578" txt_f="10993">). However, the differences in baseline QOLRAD scores in the domains of emotional stress, sleep disturbance, and vitality between adolescents and adults with moderate heartburn were clinically significant (scores varied by â¥0.5 units). In addition, differences in baseline scores for the sleep disturbance and vitality domains between adolescents and adults with severe heartburn were clinically significant (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="18541" xml_f="18542" txt_i="10993" txt_f="10994">2</offsets></xref><offsets xml_i="18549" xml_f="18551" txt_i="10994" txt_f="10996">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="18599" xml_f="18606" txt_i="10997" txt_f="11004">Table 2</offsets></label><caption><p><offsets xml_i="18626" xml_f="18717" txt_i="11004" txt_f="11095">Comparison of baseline QOLRAD scores in adolescents and adults based on heartburn severity.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th align="center" colspan="6"><offsets xml_i="18819" xml_f="18849" txt_i="11096" txt_f="11126">Heartburn Severity at Baseline</offsets></th></tr><tr><th></th><th colspan="2"><hr></hr></th><th colspan="2"><hr></hr></th><th colspan="2"><hr></hr></th></tr><tr><th></th><th align="center" colspan="2"><offsets xml_i="19011" xml_f="19015" txt_i="11126" txt_f="11130">Mild</offsets></th><th align="center" colspan="2"><offsets xml_i="19051" xml_f="19059" txt_i="11130" txt_f="11138">Moderate</offsets></th><th align="center" colspan="2"><offsets xml_i="19095" xml_f="19101" txt_i="11138" txt_f="11144">Severe</offsets></th></tr><tr><th></th><th colspan="6"><hr></hr></th></tr><tr><th align="left"><offsets xml_i="19180" xml_f="19193" txt_i="11144" txt_f="11157">QOLRAD Domain</offsets></th><th align="center"><offsets xml_i="19217" xml_f="19227" txt_i="11157" txt_f="11167">Adolescent</offsets></th><th align="center"><offsets xml_i="19251" xml_f="19256" txt_i="11167" txt_f="11172">Adult</offsets><sup><offsets xml_i="19261" xml_f="19262" txt_i="11172" txt_f="11173">a</offsets></sup></th><th align="center"><offsets xml_i="19292" xml_f="19302" txt_i="11173" txt_f="11183">Adolescent</offsets></th><th align="center"><offsets xml_i="19326" xml_f="19331" txt_i="11183" txt_f="11188">Adult</offsets><sup><offsets xml_i="19336" xml_f="19337" txt_i="11188" txt_f="11189">a</offsets></sup></th><th align="center"><offsets xml_i="19367" xml_f="19377" txt_i="11189" txt_f="11199">Adolescent</offsets></th><th align="center"><offsets xml_i="19401" xml_f="19406" txt_i="11199" txt_f="11204">Adult</offsets><sup><offsets xml_i="19411" xml_f="19412" txt_i="11204" txt_f="11205">a</offsets></sup></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="19464" xml_f="19482" txt_i="11205" txt_f="11223">Emotional distress</offsets></td><td align="center"><offsets xml_i="19506" xml_f="19509" txt_i="11224" txt_f="11227">5.4</offsets></td><td align="center"><offsets xml_i="19533" xml_f="19536" txt_i="11228" txt_f="11231">5.2</offsets></td><td align="center"><offsets xml_i="19560" xml_f="19563" txt_i="11232" txt_f="11235">4.9</offsets></td><td align="center"><offsets xml_i="19587" xml_f="19590" txt_i="11236" txt_f="11239">4.1</offsets></td><td align="center"><offsets xml_i="19614" xml_f="19617" txt_i="11240" txt_f="11243">3.5</offsets></td><td align="center"><offsets xml_i="19641" xml_f="19644" txt_i="11244" txt_f="11247">3.5</offsets></td></tr><tr><td align="left"><offsets xml_i="19675" xml_f="19692" txt_i="11248" txt_f="11265">Sleep disturbance</offsets></td><td align="center"><offsets xml_i="19716" xml_f="19719" txt_i="11266" txt_f="11269">5.4</offsets></td><td align="center"><offsets xml_i="19743" xml_f="19746" txt_i="11270" txt_f="11273">5.4</offsets></td><td align="center"><offsets xml_i="19770" xml_f="19773" txt_i="11274" txt_f="11277">5.0</offsets></td><td align="center"><offsets xml_i="19797" xml_f="19800" txt_i="11278" txt_f="11281">4.4</offsets></td><td align="center"><offsets xml_i="19824" xml_f="19827" txt_i="11282" txt_f="11285">4.8</offsets></td><td align="center"><offsets xml_i="19851" xml_f="19854" txt_i="11286" txt_f="11289">3.7</offsets></td></tr><tr><td align="left"><offsets xml_i="19885" xml_f="19904" txt_i="11290" txt_f="11309">Food/drink problems</offsets></td><td align="center"><offsets xml_i="19928" xml_f="19931" txt_i="11310" txt_f="11313">4.6</offsets></td><td align="center"><offsets xml_i="19955" xml_f="19958" txt_i="11314" txt_f="11317">5.0</offsets></td><td align="center"><offsets xml_i="19982" xml_f="19985" txt_i="11318" txt_f="11321">4.3</offsets></td><td align="center"><offsets xml_i="20009" xml_f="20012" txt_i="11322" txt_f="11325">4.0</offsets></td><td align="center"><offsets xml_i="20036" xml_f="20039" txt_i="11326" txt_f="11329">3.8</offsets></td><td align="center"><offsets xml_i="20063" xml_f="20066" txt_i="11330" txt_f="11333">3.5</offsets></td></tr><tr><td align="left"><offsets xml_i="20097" xml_f="20105" txt_i="11334" txt_f="11342">Vitality</offsets></td><td align="center"><offsets xml_i="20129" xml_f="20132" txt_i="11343" txt_f="11346">5.1</offsets></td><td align="center"><offsets xml_i="20156" xml_f="20159" txt_i="11347" txt_f="11350">5.0</offsets></td><td align="center"><offsets xml_i="20183" xml_f="20186" txt_i="11351" txt_f="11354">4.5</offsets></td><td align="center"><offsets xml_i="20210" xml_f="20213" txt_i="11355" txt_f="11358">3.9</offsets></td><td align="center"><offsets xml_i="20237" xml_f="20240" txt_i="11359" txt_f="11362">4.0</offsets></td><td align="center"><offsets xml_i="20264" xml_f="20267" txt_i="11363" txt_f="11366">3.2</offsets></td></tr><tr><td align="left"><offsets xml_i="20298" xml_f="20325" txt_i="11367" txt_f="11394">Physical/social functioning</offsets></td><td align="center"><offsets xml_i="20349" xml_f="20352" txt_i="11395" txt_f="11398">5.9</offsets></td><td align="center"><offsets xml_i="20376" xml_f="20379" txt_i="11399" txt_f="11402">6.0</offsets></td><td align="center"><offsets xml_i="20403" xml_f="20406" txt_i="11403" txt_f="11406">5.5</offsets></td><td align="center"><offsets xml_i="20430" xml_f="20433" txt_i="11407" txt_f="11410">5.1</offsets></td><td align="center"><offsets xml_i="20457" xml_f="20460" txt_i="11411" txt_f="11414">4.7</offsets></td><td align="center"><offsets xml_i="20484" xml_f="20487" txt_i="11415" txt_f="11418">4.3</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="20533" xml_f="20609" txt_i="11419" txt_f="11495">Abbreviation: QOLRAD, Quality of Life in Reflux and Dyspepsia questionnaire.</offsets></p><p><sup><offsets xml_i="20621" xml_f="20622" txt_i="11496" txt_f="11497">a</offsets></sup><offsets xml_i="20628" xml_f="20697" txt_i="11497" txt_f="11566">Data from adults are derived from a previous study by Wiklund et al [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="20729" xml_f="20731" txt_i="11566" txt_f="11568">16</offsets></xref><offsets xml_i="20738" xml_f="20740" txt_i="11568" txt_f="11570">].</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="20793" xml_f="20803" txt_i="11572" txt_f="11582">Discussion</offsets></title><p><offsets xml_i="20814" xml_f="20976" txt_i="11583" txt_f="11745">In this study, the burden of illness in adolescent patients with GERD was measured by a diseasespecific HRQOL instrument, QOLRAD, previously validated in adults [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="21008" xml_f="21010" txt_i="11745" txt_f="11747">16</offsets></xref><offsets xml_i="21017" xml_f="21224" txt_i="11747" txt_f="11954">] and used for the first time here in adolescents. Our results demonstrated that GERD has a negative effect on HRQOL in adolescents. These results are consistent with those of a recent study by Tolia et al [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="21256" xml_f="21258" txt_i="11954" txt_f="11956">15</offsets></xref><offsets xml_i="21265" xml_f="21388" txt_i="11956" txt_f="12079">], which shows that, in children aged 2 to 18 years, GERD symptoms negatively affect the QOL of children and their parents.</offsets></p><p><offsets xml_i="21395" xml_f="22298" txt_i="12080" txt_f="12983">Because no placebo control group existed in the study, it could not be determined how much of the change from baseline in QOLRAD scores was attributable directly to esomeprazole therapy. However, this study is the first to show an improvement from baseline in HRQOL in all QOLRAD domains (emotional distress, sleep disturbance, food/drink problems, vitality, and physical/social functioning) in adolescents after treatment with a PPI in a clinical trial. In addition, the trial was a safety study, and patients were randomized to different dose groups for this purpose; it was not designed to be a comparative dosing study of esomeprazole. Between-group assessments were not made, and pooling of the data allowed for a better estimate in comparison with QOLRAD data in adults. Despite these study limitations, the findings are consistent with improvement considered clinically significant (â¥0.5 units) [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="22329" xml_f="22330" txt_i="12983" txt_f="12984">9</offsets></xref><offsets xml_i="22337" xml_f="22428" txt_i="12984" txt_f="13075">] and establish a benchmark for future QOL studies in children of different ages with GERD.</offsets></p><p><offsets xml_i="22435" xml_f="22570" txt_i="13076" txt_f="13211">In adult patients, 4 weeks of treatment with the PPI esomeprazole has been shown to significantly improve QOLRAD scores from baseline [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="22601" xml_f="22602" txt_i="13211" txt_f="13212">9</offsets></xref><offsets xml_i="22609" xml_f="22610" txt_i="13212" txt_f="13213">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="22642" xml_f="22644" txt_i="13213" txt_f="13215">11</offsets></xref><offsets xml_i="22651" xml_f="22652" txt_i="13215" txt_f="13216">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="22684" xml_f="22686" txt_i="13216" txt_f="13218">13</offsets></xref><offsets xml_i="22693" xml_f="22694" txt_i="13218" txt_f="13219">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="22726" xml_f="22728" txt_i="13219" txt_f="13221">14</offsets></xref><offsets xml_i="22735" xml_f="22777" txt_i="13221" txt_f="13263">]. In the study reported by Talley et al [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="22808" xml_f="22809" txt_i="13263" txt_f="13264">9</offsets></xref><offsets xml_i="22816" xml_f="23117" txt_i="13264" txt_f="13565">], after 4 weeks of treatment with esomeprazole 20 mg, esomeprazole 40 mg, or omeprazole 20 mg daily, changes from baseline in QOLRAD domain scores ranged from 0.81 to 1.43. This unit change for adult QOL was higher slightly than the changes from baseline reported in this study in adolescents (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="23149" xml_f="23150" txt_i="13565" txt_f="13566">1</offsets></xref><offsets xml_i="23157" xml_f="23160" txt_i="13566" txt_f="13569">) [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="23191" xml_f="23192" txt_i="13569" txt_f="13570">9</offsets></xref><offsets xml_i="23199" xml_f="23228" txt_i="13570" txt_f="13599">]. Similarly, El-Dika et al [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="23260" xml_f="23262" txt_i="13599" txt_f="13601">14</offsets></xref><offsets xml_i="23269" xml_f="23419" txt_i="13601" txt_f="13751">] reported changes in domain scores after 4 weeks of treatment with esomeprazole ranging from 1.3 to 2.0. However, in a study reported by Pace et al [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="23451" xml_f="23453" txt_i="13751" txt_f="13753">11</offsets></xref><offsets xml_i="23460" xml_f="23613" txt_i="13753" txt_f="13906">], 4 weeks of treatment with esomeprazole 40 mg yielded domain changes ranging from 0.37 to 0.66, slightly lower than those observed in our study (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="23645" xml_f="23646" txt_i="13906" txt_f="13907">1</offsets></xref><offsets xml_i="23653" xml_f="23773" txt_i="13907" txt_f="14027">). Moreover, studies in adults have shown that improved QOL is maintained with esomeprazole treatment through 6 months [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="23805" xml_f="23807" txt_i="14027" txt_f="14029">11</offsets></xref><offsets xml_i="23814" xml_f="23815" txt_i="14029" txt_f="14030">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="23847" xml_f="23849" txt_i="14030" txt_f="14032">13</offsets></xref><offsets xml_i="23856" xml_f="23858" txt_i="14032" txt_f="14034">].</offsets></p><p><offsets xml_i="23865" xml_f="24274" txt_i="14035" txt_f="14444">QOLRAD scores from adults in other studies are difficult to compare with scores from this study of adolescents because the change from baseline in QOLRAD scores in sleep disturbance and food/drink problems has been shown to be associated with baseline symptom severity (none, mild, moderate, or severe); therefore, the largest changes in QOLRAD scores occur in patients with more severe symptoms at baseline [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="24306" xml_f="24308" txt_i="14444" txt_f="14446">25</offsets></xref><offsets xml_i="24315" xml_f="24622" txt_i="14446" txt_f="14753">]. An appropriate comparison of the effect of GERD on QOL between adults and adolescents would be within the baseline level of symptom severity. Therefore, we compared baseline QOLRAD scores according to baseline heartburn severity from adolescents in this study with those from adults in a separate study [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="24654" xml_f="24656" txt_i="14753" txt_f="14755">16</offsets></xref><offsets xml_i="24663" xml_f="25103" txt_i="14755" txt_f="15195">]. For patients with moderate or severe heartburn, clinically significantly greater scores were observed for adolescents compared with adults for the QOLRAD domains of emotional distress (moderate heartburn only), sleep disturbance, and vitality, indicating that moderate or severe heartburn has a more negative effect on HRQOL in adults than adolescents. However, the effect of mild heartburn on HRQOL in adolescents and adults is similar.</offsets></p></sec><sec><title><offsets xml_i="25125" xml_f="25135" txt_i="15197" txt_f="15207">Conclusion</offsets></title><p><offsets xml_i="25146" xml_f="25480" txt_i="15208" txt_f="15542">Clinically significant improvements in HRQOL from baseline values were observed in this 8-week trial of esomeprazole treatment for GERD, which suggests that esomeprazole treatment may reduce the negative effect of GERD on HRQOL, particularly in the domains of vitality, emotional distress, and problems with food/drink in adolescents.</offsets></p></sec><sec><title><offsets xml_i="25502" xml_f="25521" txt_i="15544" txt_f="15563">Competing interests</offsets></title><p><offsets xml_i="25532" xml_f="25897" txt_i="15564" txt_f="15929">TG, VT, RBC, and BDG receive grant/research support from AstraZeneca; TG, VT, and BDG are consultants to AstraZeneca; BDG and VT are consultants to Wyeth; BDG is a consultant and speaker for TAP pharmaceuticals and on the Advisory Board of Santarus, Inc.; VT receives research support from GlaxoSmithKline and Wyeth; MI, BT, and JAC are employees of AstraZeneca LP.</offsets></p></sec><sec><title><offsets xml_i="25919" xml_f="25941" txt_i="15931" txt_f="15953">Authors' contributions</offsets></title><p><offsets xml_i="25952" xml_f="27469" txt_i="15954" txt_f="17471">TG was involved in the conception and design of the manuscript, revising the manuscript critically for intellectual content, and final approval of the version to be published. VT was involved in the conception and design of the manuscript, acquisition of data, analysis and interpretation of the data, drafting the manuscript, revising the manuscript critically for intellectual content, and final approval of the version to be published. RBC was involved in acquisition of data, revising the manuscript critically for important intellectual content, and final approval of the version to be submitted. BDG was involved in the conception and design of the manuscript, analysis and interpretation of the data, revising the manuscript critically for intellectual content, and final approval of the version to be published. BT was involved in the conception and design of the manuscript, analysis and interpretation of the data, drafting the manuscript, revising the manuscript critically for intellectual content, and final approval of the version to be published. MI was involved in the conception and design of the manuscript, acquisition of data, analysis and interpretation of the data, revising the manuscript critically for intellectual content, and final approval of the version to be published. JAC was involved in the conception and design of the manuscript, analysis and interpretation of the data, revising the manuscript critically for intellectual content, and final approval of the version to be published.</offsets></p></sec><sec><title><offsets xml_i="27491" xml_f="27514" txt_i="17473" txt_f="17496">Pre-publication history</offsets></title><p><offsets xml_i="27525" xml_f="27589" txt_i="17497" txt_f="17561">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-230X/9/84/prepub"><offsets xml_i="27690" xml_f="27740" txt_i="17562" txt_f="17612">http://www.biomedcentral.com/1471-230X/9/84/prepub</offsets></ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>This study was supported by AstraZeneca LP, Wilmington, Delaware.</p><p>Data from this manuscript were presented at the North American Society for Pediatric Gastroenterology, Hepatology &amp; Nutrition (NASPGHAN) Annual meeting, October 19-22, 2006, Orlando City, Florida. The authors thank Daniel Donahue and Libby Pethick (AstraZeneca LP) for study leadership and project management, respectively; Lisa M. Klumpp, PhD, and Judy E. Fallon, PharmD (Scientific Connexions, Newtown, PA), for medical writing services funded by AstraZeneca LP; Mary Wiggin (AstraZeneca LP) for editorial assistance; the patients and their parents; and the study-site staff members.</p><p>Primary Investigators</p><p>Joel Andres, MD (Orlando, FL); Ramalingam Arumugam, MD (St Paul, MN); Phyllis Bishop, MD (Jackson, MS); Jeffrey Blumer, MD, PhD (Cleveland, OH); Jeffrey Bornstein, MD (Orlando, FL); Jean-Pierre Cezard, MD, PhD (Paris, France); Salvatore Cucchiara, MD (Rome, Italy); David DeVoid, MD (Chattanooga, TN); Frederic Gottrand, MD (Lille, France); Ivor Hill, MD (Winston Salem, NC); Elizaveta Iofel, MD (New Hyde Park, NY); Vijay Kumar, MD (Sudbury, Ontario, Canada); Chris Liacouras, MD (Philadelphia, PA); Alberto Martini, MD (Genova, Italy); Grant Matheson, MD (Parkdale, Prince Edward Island, Canada); Chantal Maurage, MD (Tours, France); Adam Mezoff, MD (Dayton, OH); Bhanu Muram, MD (Mount Pearl, Newfoundland, Canada); Oluremi Ogundimu, MD (Sudbury, Ontario, Canada); Anthony Ottley, MD (Halifax, Nova Scotia, Canada); Rabin Persad, MD (Hamilton, Ontario, Canada); Yolanda Rivas, MD (Bronx, NY); Gregory Scagnelli, MD (Binghamton, NY); Stephen Shaffer, MD (Wilmington, DE); Eduardo Tron, MD (Buffalo, NY); John Tung, MD (Wilmington, DE); Dana Ursea, MD (Phoenix, AZ); Lauren Willis, MD (Norfolk, VA); and Harland Winter, MD, PhD (Boston, MA).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Gold</surname><given-names>BD</given-names></name><name><surname>Freston</surname><given-names>JW</given-names></name><article-title>Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment</article-title><source>Pediatr Drugs</source><year>2002</year><volume>4</volume><fpage>673</fpage><lpage>685</lpage></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Ramesh</surname><given-names>P</given-names></name><name><surname>Santiago</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Gunasekaran</surname><given-names>TS</given-names></name><article-title>Prevalence of gastroesophageal reflux disease (GERD) symptoms in an African American (AA) predominant adolescent high school population [abstract]</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2001</year><volume>33</volume><fpage>421</fpage></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Gunasekaran</surname><given-names>TS</given-names></name><name><surname>Dahlberg</surname><given-names>M</given-names></name><name><surname>Ramesh</surname><given-names>P</given-names></name><name><surname>Namachivayam</surname><given-names>G</given-names></name><article-title>Prevalence and associated features of gastroesophageal reflux symptoms in a Caucasianpredominant adolescent school population</article-title><source>Dig Dis Sci</source><year>2008</year><volume>53</volume><fpage>2373</fpage><lpage>2379</lpage><pub-id pub-id-type="doi">10.1007/s10620-007-0150-5</pub-id><pub-id pub-id-type="pmid">18204971</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Asokan</surname><given-names>S</given-names></name><name><surname>Ramesh</surname><given-names>P</given-names></name><name><surname>Gunasekaran</surname><given-names>TS</given-names></name><name><surname>Creech</surname><given-names>S</given-names></name><article-title>Prevalence of gastroesophageal reflux disease (GERD) symptoms in a Hispanic American adolescent [abstract]</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2003</year><volume>37</volume><fpage>337</fpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Nelson</surname><given-names>SP</given-names></name><name><surname>Chen</surname><given-names>EH</given-names></name><name><surname>Syniar</surname><given-names>GM</given-names></name><name><surname>Christoffel</surname><given-names>KK</given-names></name><collab>for Pediatric Practice Research Group</collab><article-title>Prevalence of symptoms of gastroesophageal reflux during childhood</article-title><source>Arch Pediatr Adolesc Med</source><year>2000</year><volume>154</volume><fpage>150</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">10665601</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Wiklund</surname><given-names>I</given-names></name><article-title>Review of the quality of life and burden of illness in gastroesophageal reflux disease</article-title><source>Dig Dis</source><year>2004</year><volume>22</volume><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1159/000080308</pub-id><pub-id pub-id-type="pmid">15383750</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Havelund</surname><given-names>T</given-names></name><name><surname>Lind</surname><given-names>T</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Glise</surname><given-names>H</given-names></name><name><surname>Hernqvist</surname><given-names>H</given-names></name><name><surname>Lauritsen</surname><given-names>K</given-names></name><name><surname>Lundell</surname><given-names>L</given-names></name><name><surname>Pedersen</surname><given-names>SA</given-names></name><name><surname>Carlsson</surname><given-names>R</given-names></name><name><surname>Junghard</surname><given-names>O</given-names></name><name><surname>StubberÃ¶d</surname><given-names>A</given-names></name><name><surname>Anker-Hansen</surname><given-names>O</given-names></name><article-title>Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole</article-title><source>Am J Gastroenterol</source><year>1999</year><volume>94</volume><fpage>1782</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.1999.01206.x</pub-id><pub-id pub-id-type="pmid">10406235</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Revicki</surname><given-names>DA</given-names></name><name><surname>Crawley</surname><given-names>JA</given-names></name><name><surname>Zodet</surname><given-names>MW</given-names></name><name><surname>Levine</surname><given-names>DS</given-names></name><name><surname>Joelsson</surname><given-names>BO</given-names></name><article-title>Complete resolution of heartburn symptoms and health-related quality of life in patients with gastrooesophageal reflux disease</article-title><source>Aliment Pharmacol Ther</source><year>1999</year><volume>13</volume><fpage>1621</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.1999.00669.x</pub-id><pub-id pub-id-type="pmid">10594397</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Fullerton</surname><given-names>S</given-names></name><name><surname>Junghard</surname><given-names>O</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><article-title>Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments</article-title><source>Am J Gastroenterol</source><year>2001</year><volume>96</volume><fpage>1998</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2001.03932.x</pub-id><pub-id pub-id-type="pmid">11467624</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>De La Loge</surname><given-names>C</given-names></name><name><surname>Trudeau</surname><given-names>E</given-names></name><name><surname>Marquis</surname><given-names>P</given-names></name><name><surname>Revicki</surname><given-names>DA</given-names></name><name><surname>Rentz</surname><given-names>AM</given-names></name><name><surname>Stanghellini</surname><given-names>V</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Kahrilas</surname><given-names>P</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Dubois</surname><given-names>D</given-names></name><article-title>Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders</article-title><source>Clin Gastroenterol Hepatol</source><year>2004</year><volume>2</volume><fpage>778</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1016/S1542-3565(04)00349-0</pub-id><pub-id pub-id-type="pmid">15354278</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Pace</surname><given-names>F</given-names></name><name><surname>Negrini</surname><given-names>C</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Rossi</surname><given-names>C</given-names></name><name><surname>Savarino</surname><given-names>V</given-names></name><collab>for The Italian One Investigators Study Group</collab><article-title>Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>22</volume><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2005.02558.x</pub-id><pub-id pub-id-type="pmid">16098002</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Madisch</surname><given-names>A</given-names></name><name><surname>Kulich</surname><given-names>KR</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Ziegler</surname><given-names>K</given-names></name><name><surname>BayerdÃ¶rffer</surname><given-names>E</given-names></name><name><surname>Miehlke</surname><given-names>S</given-names></name><name><surname>Labenz</surname><given-names>J</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Wiklund</surname><given-names>IK</given-names></name><article-title>Impact of reflux disease on general and disease-related quality of life--evidence from a recent comparative methodological study in Germany</article-title><source>Z Gastroenterol</source><year>2003</year><volume>41</volume><fpage>1137</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1055/s-2003-45277</pub-id><pub-id pub-id-type="pmid">14661122</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>ÃN</given-names></name><name><surname>Bergheim</surname><given-names>R</given-names></name><name><surname>Fagertun</surname><given-names>H</given-names></name><name><surname>Lund</surname><given-names>H</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Moum</surname><given-names>B</given-names></name><article-title>Long-term management of patients with symptoms of gastro-oesophageal reflux disease--a Norwegian randomized prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting</article-title><source>Int J Clin Pract</source><year>2006</year><volume>60</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/j.1368-5031.2006.00768.x</pub-id><pub-id pub-id-type="pmid">16409423</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>El-Dika</surname><given-names>S</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Degl'innocenti</surname><given-names>A</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Fallone</surname><given-names>CA</given-names></name><name><surname>Tanser</surname><given-names>L</given-names></name><name><surname>Veldhuyzen van Zanten</surname><given-names>S</given-names></name><name><surname>Heels-Ansdell</surname><given-names>D</given-names></name><name><surname>Wahlqvist</surname><given-names>P</given-names></name><name><surname>Chiba</surname><given-names>N</given-names></name><name><surname>Barkun</surname><given-names>AN</given-names></name><name><surname>Austin</surname><given-names>P</given-names></name><name><surname>SchÃ¼nemann</surname><given-names>HJ</given-names></name><article-title>The impact of illness in patients with moderate to severe gastro-esophageal reflux disease</article-title><source>BMC Gastroenterol</source><year>2005</year><volume>5</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1186/1471-230X-5-23</pub-id><pub-id pub-id-type="pmid">16004616</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Tolia</surname><given-names>V</given-names></name><name><surname>Essenbacher</surname><given-names>L</given-names></name><name><surname>Boyer</surname><given-names>K</given-names></name><name><surname>Ager</surname><given-names>J</given-names></name><article-title>Gastroesophageal reflux disease (GERD) questionnaire to assess quality of life (QOL) in patients and parents [abstract: poster session]</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2004</year><volume>39</volume><fpage>S424</fpage><lpage>S425</lpage></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Wiklund</surname><given-names>IK</given-names></name><name><surname>Junghard</surname><given-names>O</given-names></name><name><surname>Grace</surname><given-names>E</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Kamm</surname><given-names>M</given-names></name><name><surname>Veldhuyzen van Zanten</surname><given-names>S</given-names></name><name><surname>ParÃ©</surname><given-names>P</given-names></name><name><surname>Chiba</surname><given-names>N</given-names></name><name><surname>Leddin</surname><given-names>DS</given-names></name><name><surname>Bigard</surname><given-names>MA</given-names></name><name><surname>Colin</surname><given-names>R</given-names></name><name><surname>Schoenfeld</surname><given-names>P</given-names></name><article-title>Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD)</article-title><source>Eur J Surg Suppl</source><year>1998</year><volume>583</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">10027672</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Rudolph</surname><given-names>CD</given-names></name><name><surname>Mazur</surname><given-names>LJ</given-names></name><name><surname>Liptak</surname><given-names>GS</given-names></name><name><surname>Baker</surname><given-names>RD</given-names></name><name><surname>Boyle</surname><given-names>JT</given-names></name><name><surname>Colletti</surname><given-names>RB</given-names></name><name><surname>Gerson</surname><given-names>WT</given-names></name><name><surname>Werlin</surname><given-names>SL</given-names></name><article-title>Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2001</year><volume>32</volume><issue>suppl 2</issue><fpage>S1</fpage><lpage>S31</lpage><pub-id pub-id-type="doi">10.1097/00005176-200100002-00001</pub-id><pub-id pub-id-type="pmid">11525610</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>DeVault</surname><given-names>KR</given-names></name><name><surname>Castell</surname><given-names>DO</given-names></name><article-title>Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><fpage>190</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.41217.x</pub-id><pub-id pub-id-type="pmid">15654800</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Richter</surname><given-names>JE</given-names></name><name><surname>Kahrilas</surname><given-names>PJ</given-names></name><name><surname>Johanson</surname><given-names>J</given-names></name><name><surname>Maton</surname><given-names>P</given-names></name><name><surname>Breiter</surname><given-names>JR</given-names></name><name><surname>Hwang</surname><given-names>C</given-names></name><name><surname>Marino</surname><given-names>V</given-names></name><name><surname>Hamelin</surname><given-names>B</given-names></name><name><surname>Levine</surname><given-names>JG</given-names></name><collab>for Esomeprazole Study Investigators</collab><article-title>Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial</article-title><source>Am J Gastroenterol</source><year>2001</year><volume>96</volume><fpage>656</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2001.03600.x</pub-id><pub-id pub-id-type="pmid">11280530</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Benjamin</surname><given-names>SB</given-names></name><name><surname>Vakil</surname><given-names>NB</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Lamet</surname><given-names>M</given-names></name><name><surname>Whipple</surname><given-names>J</given-names></name><name><surname>Damico</surname><given-names>D</given-names></name><name><surname>Hamelin</surname><given-names>B</given-names></name><article-title>Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety</article-title><source>Am J Gastroenterol</source><year>2001</year><volume>96</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2001.03443.x</pub-id><pub-id pub-id-type="pmid">11197282</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Fiedorek</surname><given-names>S</given-names></name><name><surname>Tolia</surname><given-names>V</given-names></name><name><surname>Gold</surname><given-names>BD</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Stolle</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Gremse</surname><given-names>D</given-names></name><article-title>Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2005</year><volume>40</volume><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1097/01.MPG.0000155369.54464.41</pub-id><pub-id pub-id-type="pmid">15735486</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Hassall</surname><given-names>E</given-names></name><name><surname>Israel</surname><given-names>D</given-names></name><name><surname>Shepherd</surname><given-names>R</given-names></name><name><surname>Radke</surname><given-names>M</given-names></name><name><surname>DalvÃ¤g</surname><given-names>A</given-names></name><name><surname>SkÃ¶ld</surname><given-names>B</given-names></name><name><surname>Junghard</surname><given-names>O</given-names></name><name><surname>Lundborg</surname><given-names>P</given-names></name><collab>for International Pediatric Omeprazole Study Group</collab><article-title>Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements</article-title><source>J Pediatr</source><year>2000</year><volume>137</volume><fpage>800</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1067/mpd.2000.109607</pub-id><pub-id pub-id-type="pmid">11113836</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Gold</surname><given-names>BD</given-names></name><name><surname>Gunasekaran</surname><given-names>T</given-names></name><name><surname>Tolia</surname><given-names>V</given-names></name><name><surname>Wetzler</surname><given-names>G</given-names></name><name><surname>Conter</surname><given-names>H</given-names></name><name><surname>Traxler</surname><given-names>B</given-names></name><name><surname>Illueca</surname><given-names>M</given-names></name><article-title>Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2007</year><volume>45</volume><fpage>520</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e318148c17c</pub-id><pub-id pub-id-type="pmid">18030228</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Kulich</surname><given-names>K</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Junghard</surname><given-names>O</given-names></name><article-title>Factor structure of the quality of life in reflux and dyspepsia (QOLRAD) questionnaire evaluated in patients with heartburn predominant reflux disease</article-title><source>Qual Life Res</source><year>2003</year><volume>12</volume><fpage>699</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1023/A:1025192100450</pub-id><pub-id pub-id-type="pmid">14516179</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Junghard</surname><given-names>O</given-names></name><name><surname>Wiklund</surname><given-names>IK</given-names></name><article-title>Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease</article-title><source>Eur J Gastroenterol Hepatol</source><year>2007</year><volume>19</volume><fpage>555</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1097/MEG.0b013e328133f2d1</pub-id><pub-id pub-id-type="pmid">17556901</pub-id></mixed-citation></ref></ref-list></back></article>